Aroa Biosurgery Ltd
Aroa Biosurgery Limited is a soft-tissue regeneration company.
The business
Aroa Biosurgery Limited is a soft-tissue regeneration company. It develops, manufactures, sells, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from the ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that serve as the building blocks for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, Symphony, and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM designed for soft tissue repair, reinforcement, and complex wounds.
Small Caps Research
No research on Aroa Biosurgery Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise ARX based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Aroa Biosurgery Sets Ambitious FY27 Targets after Exceeding FY26 Guidance
Aroa Biosurgery beats FY26 guidance as Myriad drives revenue 23% YoY; FY27 targets NZ$115-125m, Symphony catalyst; cash-rich, debt-free.
Aroa Biosurgery Reports NZ$44.9m in Product Revenue for First Six Months of FY26
Aroa Biosurgery (ASX: ARX) has reported total product revenue of NZ$44.9 million for the first six months of financial year 2026, representing growth of 14% on the previous corresponding period.
Aroa Biosurgery maintains cash flow momentum as Myriad Matrix product sales hit record high
Soft tissue regeneration specialist Aroa Biosurgery (ASX: ARX) has posted its second consecutive quarter of positive cash flow, in a period that also saw the company reach a key milestone with over 100 published peer reviews now validating its ECM platform in pre-clinical and clinical studies. Cash flow for the three months to end-March totalled […]
Aroa Biosurgery gains US and EU clearance for complex wound healing products
Newly-listed soft tissue regeneration company Aroa Biosurgery (ASX: ARX) has announced that its Symphony and Myriad complex wound healing products have gained clearance from international regulators. Symphony has received approval from the US Food and Drug Administration, while Myriad received European regulatory approval via CE Mark certification. Both approvals were confirmed by Aroa this morning […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.